source
- Definium’s LSD therapy cuts anxiety scores in second late-stage trialDefinium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…
- Public backing fuels FDA hearing on psychedelic therapies and potential COMP360 approvalThe FDA is holding a hearing on Monday to discuss the future of psychedelic drug development, after a wave of public comments expressed strong support for further research. Analysts say the suppor…